VIRAX BIOLABS GROUP LTD (VRAX) Fundamental Analysis & Valuation

NASDAQ:VRAX • KYG9495L1251

Current stock price

0.1765 USD
+0 (+1.91%)
At close:
0.1742 USD
0 (-1.3%)
After Hours:

This VRAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VRAX Profitability Analysis

1.1 Basic Checks

  • VRAX had negative earnings in the past year.
  • VRAX had a negative operating cash flow in the past year.
  • VRAX had negative earnings in each of the past 5 years.
  • In the past 5 years VRAX always reported negative operating cash flow.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • The Return On Assets of VRAX (-98.75%) is worse than 93.00% of its industry peers.
  • VRAX has a worse Return On Equity (-106.24%) than 74.00% of its industry peers.
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROIC N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. VRAX Health Analysis

2.1 Basic Checks

  • VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VRAX has been increased compared to 1 year ago.
  • The number of shares outstanding for VRAX has been reduced compared to 5 years ago.
  • VRAX has a worse debt/assets ratio than last year.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • Based on the Altman-Z score of 0.67, we must say that VRAX is in the distress zone and has some risk of bankruptcy.
  • VRAX has a worse Altman-Z score (0.67) than 73.00% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that VRAX is not too dependend on debt financing.
  • VRAX's Debt to Equity ratio of 0.09 is fine compared to the rest of the industry. VRAX outperforms 76.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC11.46%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 11.35 indicates that VRAX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 11.35, VRAX belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
  • VRAX has a Quick Ratio of 11.20. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
  • VRAX's Quick ratio of 11.20 is amongst the best of the industry. VRAX outperforms 97.00% of its industry peers.
Industry RankSector Rank
Current Ratio 11.35
Quick Ratio 11.2
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VRAX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.89% over the past year.
  • The Revenue for VRAX has decreased by -96.47% in the past year. This is quite bad
  • The Revenue for VRAX have been decreasing by -42.47% on average. This is quite bad
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue is expected to grow by 16.04% on average over the next years. This is quite good.
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

4

4. VRAX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VRAX. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 4.33, which indicates a rather cheap valuation of VRAX.
  • Based on the Price/Forward Earnings ratio, VRAX is valued cheaper than 99.00% of the companies in the same industry.
  • VRAX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.70.
Industry RankSector Rank
PE N/A
Fwd PE 4.33
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • VRAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRAX Dividend Analysis

5.1 Amount

  • VRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VRAX Fundamentals: All Metrics, Ratios and Statistics

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (3/23/2026, 8:23:37 PM)

After market: 0.1742 0 (-1.3%)

0.1765

+0 (+1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)12-13
Inst Owners11.57%
Inst Owner ChangeN/A
Ins Owners4.61%
Ins Owner Change0%
Market Cap1.31M
Revenue(TTM)3.00K
Net Income(TTM)-5.64M
Analysts82.86
Price Target1.02 (477.9%)
Short Float %0.79%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.33
P/S 436.54
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)0.04
Fwd EY23.12%
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.76%
Cap/Sales 16580%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.35
Quick Ratio 11.2
Altman-Z 0.67
F-Score1
WACC11.46%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4134.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%
EBIT growth 1Y6.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.95%
OCF growth 3YN/A
OCF growth 5YN/A

VIRAX BIOLABS GROUP LTD / VRAX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?

ChartMill assigns a fundamental rating of 3 / 10 to VRAX.


What is the valuation status for VRAX stock?

ChartMill assigns a valuation rating of 4 / 10 to VIRAX BIOLABS GROUP LTD (VRAX). This can be considered as Fairly Valued.


Can you provide the profitability details for VIRAX BIOLABS GROUP LTD?

VIRAX BIOLABS GROUP LTD (VRAX) has a profitability rating of 0 / 10.